(13 August, 2026, Shanghai China) On August 13, Fosun Pharma (600196.SH; 02196.HK) announced that its self-developed DPP-1 inhibitor innovative drug FXS7553 (the "New Drug") for the treatment of chronic obstructive pulmonary disease (COPD) has recently completed the first patient dosing in a Phase 2 clinical trial in Chinese mainland (excluding Hong Kong SAR, Macau SAR, and Taiwan region).

FXS7553 is a small molecule orally administered DPP-1 inhibitor independently developed by Fosun Pharma. It reduces neutrophilic inflammatory responses and mitigates the consequent airway damage by inhibiting DPP-1-mediated activation of neutrophil serine proteases. As of now, another under-development indication of FXS7553 for the treatment of non-cystic fibrosis bronchiectasis is under Phase 2 clinical trial stage in Chinese mainland. 

The primary goals of stable COPD treatment are to alleviate symptoms, reduce acute exacerbations, and slow disease progression. Current standard treatments, primarily bronchodilators and inhaled corticosteroids, can relieve symptoms to a certain extent but have limited efficacy in preventing acute exacerbations or slowing disease progression. Neutrophilic inflammation represents the predominant inflammatory phenotype in COPD, affecting the majority of patients. Over the past two decades, only three novel mechanism-based therapies have been approved for COPD in China, two of which target type 2 inflammation, leaving the predominant non-type 2/neutrophilic inflammatory phenotype without targeted treatment options. To date, no small-molecule oral inhibitor with the same molecular mechanism has been approved for marketing in China.

-END-

About Fosun Pharma

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.

Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.

Looking ahead, guided by the strategy of “Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health.

For more information about the Group, please visit the company website: https://www.fosunpharma.com/en/